LIVN (LivaNova) ROCE %: 8.06% (As of Mar. 2026)

What is LivaNova ROCE %?

LivaNova LIVN +1.40% 76 ROCE % is 8.06% as of Mar. 2026. GuruFocus rates LIVN with a GF Score™ of 76/100 and a GF Value™ of $62.48 (Modestly Overvalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. LivaNova's annualized ROCE % for the quarter that ended in Mar. 2026 was 8.06%.

LivaNova (NAS:LIVN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

LivaNova ROCE % Related Terms

LivaNova ROCE % Historical Data

* Premium members only.

The historical data trend for LivaNova's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LivaNova ROCE % Chart

LivaNova Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-4.13

-1.54

-1.09

7.19

-8.77

LivaNova Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-61.12	10.43	10.51	8.73	8.06

76GF Score

LivaNova PLC LIVN

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

LivaNova ROCE % Calculation

LivaNova's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-171.495	/	( ( (2506.389 - 392.125)	+	(2606.053 - 808.072) )	/ 2 )
	=	-171.495	/	( (2114.264	+	1797.981)	/ 2 )
	=	-171.495	/	1956.1225
	=	-8.77 %

LivaNova's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	143.2	/	( ( (2606.053 - 808.072)	+	(2516.4 - 762.5) )	/ 2 )
	=	143.2	/	( ( 1797.981	+	1753.9 )	/ 2 )
	=	143.2	/	1775.9405
	=	8.06 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 8.06% mean?

LivaNova (LIVN) has a ROCE % of 8.06% as of Mar. 2026.

Is LivaNova's ROCE % too high?

LivaNova's current ROCE % is 8.06%. The Medical Devices & Instruments industry median ROCE % is 2.23. LivaNova's value of 8.06% is 261.4% above this industry median. Overall, LivaNova has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.

How does LivaNova's ROCE % compare to IRTC and HAE?

LivaNova's ROCE % of 8.06% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. LivaNova's value of 8.06% is 261.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LivaNova's current ROCE % of 8.06% is 261.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LivaNova's current ROCE % is 8.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is LivaNova stock overvalued right now?

Based on GuruFocus' analysis, LivaNova (LIVN) is currently considered Modestly Overvalued. The stock's GF Value™ is $62.48, compared to a current price of $81.05 — trading 29.7% above its estimated fair value. The current ROCE % is 8.06% and 261.4% above the Medical Devices & Instruments industry median of 2.23. LivaNova's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For LivaNova (LIVN), the current ROCE % is 8.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LivaNova (LIVN) Overvalued in 2026?

Based on GuruFocus' analysis, LivaNova stock appears to be overvalued. The current stock price of $81.05 is trading 29.7% above its estimated GF Value™ of $62.48. GuruFocus considers LivaNova to be Modestly Overvalued.

Key valuation signals for LIVN:

ROCE %: 8.06%
GF Value™: $62.48 vs. price of $81.05 (29.7% above fair value)
GF Score™: 76/100 with 7 warning signs
Industry Position: 261.4% above the Medical Devices & Instruments median

No single metric tells the full story. See the LIVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LivaNova Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies IRTC HAE ITGR TMDX AXGN ESTA GKOS NVCR NEOG UFPT ABT SYK MDT BSX EW XTER:SHL DXCM GEHC SZSE:300760 XAMS:PHIA

Other Exchanges LIA:Germany

Address 20 Eastbourne Terrace, London, GBR, W2 6LG

Website https://www.livanova.com

UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

76GF Score

Get the complete analysis for LIVN

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$81.05

Price

$62.48

GF Value

View LIVN Analysis

See ROCE % data for all stocks →